DV Biomed Co., Ltd. (TPEX:6539)
Taiwan · Delayed Price · Currency is TWD 41.50
-0.50 (-1.19%)
Aug 19, 2026, 10:11 AM CST
DV Biomed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 795.19 | 794.18 | 573.57 | 618.85 | 1,866 | 1,827 | |
Revenue Growth | 11.59% | 38.46% | -7.32% | -66.84% | 2.13% | 0.85% |
Cost of Revenue | 218.48 | 227.55 | 149.07 | 135.5 | 827.29 | 804.96 |
Gross Profit | 576.72 | 566.63 | 424.5 | 483.35 | 1,039 | 1,022 |
Selling, General & Admin | 495.79 | 546.71 | 310.89 | 325.03 | 639.72 | 592.92 |
Research & Development | 6.09 | 5.02 | 5.28 | 8.25 | 12.84 | 12.44 |
Operating Expenses | 502.51 | 551.77 | 314.88 | 334.39 | 651.96 | 603.57 |
Operating Income | 74.21 | 14.86 | 109.63 | 148.96 | 386.91 | 418.65 |
Interest Expense | -1.11 | -1.5 | -1.68 | -0.16 | -5.21 | -4.45 |
Interest & Investment Income | 5.9 | 5.9 | 5.44 | 6.01 | 2.22 | 0.83 |
Earnings From Equity Investments | - | - | - | - | -26.15 | -27.97 |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.1 |
Other Non Operating Income (Expenses) | 14.68 | -9.14 | 12.42 | 6.32 | 7.28 | -2.55 |
EBT Excluding Unusual Items | 93.69 | 10.11 | 125.81 | 161.13 | 365.06 | 384.42 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.3 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -4.73 |
Asset Writedown | - | - | - | - | - | 13.91 |
Other Unusual Items | - | - | - | - | - | 1.87 |
Pretax Income | 93.69 | 10.11 | 125.81 | 161.13 | 365.06 | 395.76 |
Income Tax Expense | 16.71 | 2.02 | 23.19 | 30.17 | 76.06 | 91.19 |
Earnings From Continuing Operations | 76.97 | 8.09 | 102.62 | 130.97 | 289 | 304.58 |
Earnings From Discontinued Operations | -0.36 | -0.35 | -0.83 | 9.34 | -7.74 | - |
Net Income to Company | 76.62 | 7.74 | 101.79 | 140.3 | 281.26 | 304.58 |
Minority Interest in Earnings | - | - | -12.71 | 22.61 | - | - |
Net Income | 76.62 | 7.74 | 89.08 | 162.91 | 281.26 | 304.58 |
Net Income to Common | 76.62 | 7.74 | 89.08 | 162.91 | 281.26 | 304.58 |
Net Income Growth | 46.26% | -91.31% | -45.32% | -42.08% | -7.66% | 1.05% |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | 25 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | 25 |
Shares Change | 0.07% | -0.09% | -0.18% | -0.17% | -0.76% | -0.81% |
EPS (Basic) | 3.15 | 0.32 | 3.66 | 6.69 | 11.51 | 12.37 |
EPS (Diluted) | 3.14 | 0.32 | 3.65 | 6.67 | 11.49 | 12.35 |
EPS Growth | 54.16% | -91.36% | -45.22% | -41.97% | -6.94% | 1.82% |
Free Cash Flow | 50.39 | 29.35 | 117.52 | 67.09 | 401.83 | 460.37 |
Free Cash Flow Per Share | 2.07 | 1.21 | 4.82 | 2.75 | 16.43 | 18.68 |
Dividend Per Share | 0.600 | 0.600 | 2.373 | 7.367 | 13.014 | 10.590 |
Dividend Growth | -60.67% | -74.71% | -67.79% | -43.40% | 22.89% | 10.00% |
Gross Margin | 72.53% | 71.35% | 74.01% | 78.11% | 55.67% | 55.95% |
Operating Margin | 9.33% | 1.87% | 19.11% | 24.07% | 20.73% | 22.91% |
Profit Margin | 9.63% | 0.97% | 15.53% | 26.32% | 15.07% | 16.67% |
Free Cash Flow Margin | 6.34% | 3.70% | 20.49% | 10.84% | 21.53% | 25.20% |
EBITDA | 88.34 | 32.02 | 114.02 | 160.47 | 468.9 | 542.47 |
EBITDA Margin | 11.11% | 4.03% | 19.88% | 25.93% | 25.13% | 29.69% |
D&A For EBITDA | 14.12 | 17.16 | 4.4 | 11.51 | 81.99 | 123.82 |
EBIT | 74.21 | 14.86 | 109.63 | 148.96 | 386.91 | 418.65 |
EBIT Margin | 9.33% | 1.87% | 19.11% | 24.07% | 20.73% | 22.91% |
Effective Tax Rate | 17.84% | 19.99% | 18.43% | 18.72% | 20.83% | 23.04% |
Advertising Expenses | - | - | - | - | - | 185.85 |